Silence Therapeutics Plc - ADR Stock

$18.25

4.70% yesterday

Nasdaq, Sep 27, 10:00 pm CET

ISIN

US82686Q1013

Symbol

SLN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Overview Dividends Analysts Charts News Strategies

Silence Therapeutics Plc - ADR Stock price

$18.25

-1.25 6.41% 5Y

Nasdaq, Closing price Fri, Sep 27 2024

+0.82 4.70%

ISIN

US82686Q1013

Symbol

SLN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Key metrics

Market capitalization	$815.69m
Enterprise Value	$626.82m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	27.70
P/S ratio (TTM) P/S ratio	36.04
P/B ratio (TTM) P/B ratio	5.74
Revenue growth (TTM) Revenue growth	-34.91%
Revenue (TTM) Revenue	$22.63m
EBIT (operating result TTM) EBIT	$-60.96m
Free Cash Flow (TTM) Free Cash Flow	$-33.93m
Cash position	$189.10m
EPS (TTM) EPS	$-1.21
P/E forward	negative
P/S forward	28.91
EV/Sales forward	22.22
Short interest	0.86%

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Get Started for Free Today

Silence Therapeutics Plc - ADR Stock Analysis

Unlock Scores for Free

??

6 Analysts have issued a Silence Therapeutics Plc - ADR forecast:

6x Buy

100%

More details on Analyst Estimates Including Price Targets

6 Analysts have issued a Silence Therapeutics Plc - ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Silence Therapeutics Plc - ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	23 23	35% 35% 100%
- Direct Costs	9.85 9.85	42% 42% 44%
Gross Profit	13 13	29% 29% 56%
- Selling and Administrative Expenses	24 24	0% 0% 106%
- Research and Development Expense	49 49	4% 4% 217%
EBITDA	-60 -60	5% 5% -267%
- Depreciation and Amortization	0.61 0.61	0% 0% 3%
EBIT (Operating Income) EBIT	-61 -61	5% 5% -269%
Net Profit	-50 -50	1% 1% -222%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Silence Therapeutics Plc - ADR Stock News

Positive

Seeking Alpha

●

19 days ago

Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy'

Silence Therapeutics focuses on RNA interference therapies, with its lead candidates targeting cardiovascular and hematological diseases via the mRNAi GOLD platform. Zerlasiran, the company's main value driver, aims to reduce lipoprotein(a) levels, potentially lowering cardiovascular risks in 20-25% of the global population. Divesiran shows promise in early trials for Polycythemia Vera. Early c...

Positive

Seeking Alpha

●

22 days ago

Silence: Additional siRNA Drug Data Leads To Next Stages Of Development

Silence Therapeutics plc's positive results achieved from phase 1 SANRECO study using divesiran for the treatment of patients with polycythemia vera. The global polycythemia vera treatment market size is predicted to reach $45 billion by the end of 2036. Full detailed results from the phase 1 SANRECO study, using divesiran for the treatment of patients with polycythemia vera, are to be presente...

Neutral

Business Wire

●

about one month ago

Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that management will present company overviews at the following conferences: Morgan Stanley Global Healthcar...

More Silence Therapeutics Plc - ADR News

Company Profile

Silence Therapeutics Plc engages in the discovery, delivery and development of ribonucleic acid (RNA) therapeutics. It develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.

Head office	United Kingdom
CEO	Craig Tooman
Employees	109
Founded	1994
Website	www.silence-therapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now